KCT0007720招募中未知
A 12-week, randomized, double-blind, placebo-controlled human application trial to evaluate the efficacy and safety of ACP_01 on skin wrinkle improvement and moisturizing
Daehan Chemtech Co., Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 35(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1) Men and women over the age of 35 and under the age of 60
- •2) Those whose eye wrinkles are Grade 3 or higher on both the left and right sides in the visual evaluation
- •3) Those with a moisture retention of 49 AU or less in both cheeks measured by Corneometer® at visits 1 and 2
- •4) A person who has agreed to participate in this human application test before the start of the human application test and filled out the Informed Consent Form
排除标准
- •Those who meet one or more of the following conditions are excluded from the human test subjects.
- •1) Those who are currently being treated for severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, infectious disease or malignancy
- •2) People with mental disorders such as schizophrenia, depression, drug addiction, alcohol use/induced disorder, etc.
- •3) Those with skin diseases such as atopic dermatitis and psoriasis
- •4) Those with skin abnormalities such as spots, acne, erythema, and capillary dilatation at the test site
- •5) Smokers or those who have not quit smoking for less than 1 year
- •6) Those who have undergone facial treatment such as botox or fillers within 6 months based on visit 1, or who have undergone facial skin dermabrasion or other skin care within 1 month (30 days)
- •7) Those who have used steroid-containing skin external agents on the face or oral retinoids/steroids within 3 months from Visit 1
- •8) Those who have taken anti-obesity drugs (fat absorption inhibitors, appetite suppressants, etc.), psychiatric drugs such as depression and schizophrenia, contraceptives or hormones, or diuretics within 1 month of visit 1.
- •9) Medicines and health functional foods aimed at improving skin wrinkles and moisturizing effects within 2 weeks of visit 1 (health functional foods containing antioxidants, hyaluronic acid, collagen, evening primrose oil, vitamins A, C, E containing medicines and health functions food, etc.)
- •10) Those who have used functional cosmetics for wrinkle improvement (retinoids, AHA, etc.), highly moisturizing cosmetics, or skin care devices (LED mask, ion booster, etc.) within 2 weeks of visit 1
- •11) Those with AST (GOT) or ALT (GPT) of 120 IU/L or more or ?-GTP of 180 IU/L or more
- •12) Those whose Creatinine is 2.4 mg/dL or higher
- •13) Those with TSH of 0.1 µIU/mL or less or 10 µIU/mL or more
- •14) Patients with uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg, measurement standard after 10 minutes of rest for human subjects)
- •15) Patients with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher)
- •16) Those who are pregnant, lactating, or planning to become pregnant during this human application test period
- •17) Those who have participated in other interventional clinical trials (including human trials) within 1 month from Visit 1, or who plan to participate in other interventional clinical trials (including human trials) after the start of this human trial
- •18) Those who are sensitive to or allergic to the food ingredients for this human application test
- •19) Those who are judged inappropriate by the investigator for other reasons
研究者
相似试验
招募中
Unknown
A human trial of SMSP8118 on improvement of Liver functioDiseases of the digestive systemKCT0009369Jeonbuk National University Hospital80
进行中（未招募）
1 期
A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury - C10953/3067/ES/MPatients with excessive Sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI)MedDRA version: 12.0Level: LLTClassification code 10060690Term: Traumatic brain injuryMedDRA version: 12.0Level: LLTClassification code 10015595Term: Excessive daytime sleepinessEUCTR2009-014545-83-FRCephalon Inc.620
进行中（未招募）
不适用
A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d.) in patients aged = 65 years with overactive bladder - Not applicableOveractive bladder (OAB)EUCTR2004-002894-21-DEovartis Pharma Services AG399
招募中
Unknown
Clinical trial to evaluate the effectiveness and safety of EEFE on cognitive function improvementKCT0009469Ewha Womens University80
招募中
不适用
Evalution of the Effectiveness and Safety of ChondroT on the Knee ArthritisKCT0007997Dongshin University Mokpo Oriental Hospital160